MRC Centre for Virus Research


Services Available

The CVR, with support from LifeArc and the MRC, has established a translational facility for antiviral drug screening and resistance development. CRUSH (COVID-19 Resistance and Drug-Screening Hub) is a fully integrated hub with the biocontainment facilities and expertise to support pre-clinical studies of high consequence viruses, including SARS-CoV-2.